Misyo (Methadone Hydrochloride)

Methadone Hydrochloride, the active ingredient in Misyo, is an opioid agonist presented as an oral formulation for systemic use. It is employed to manage opioid dependence and to provide long‑acting analgesia for patients with severe chronic pain in adult populations under medical supervision. The medication is supplied in compliance with European Union pharmaceutical standards and is intended for prescription‑only distribution.

GNH USA supplies Misyo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with a focus on reliable quality and regulatory adherence.

Methadone Hydrochloride acts on the opioid system to address dependence and pain conditions.

Opioid dependence: helps suppress withdrawal symptoms and supports maintenance therapy. Severe chronic pain: provides long‑acting analgesia for patients requiring strong opioid control. Palliative care: offers effective pain relief for end‑of‑life patients where other opioids are insufficient.

Methadone Hydrochloride may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Constipation - Dizziness - Dry mouth

Serious or Rare Side Effects: - Respiratory depression - QT interval prolongation - Anaphylactic reaction

When prescribing Methadone Hydrochloride, clinicians should observe several safety measures.

Assess opioid tolerance: evaluate patient history before initiating therapy. Monitor respiratory function: observe breathing rate and oxygen saturation regularly. Evaluate cardiac status: obtain baseline ECG to detect QT prolongation risk. Avoid use in acute intoxication: do not prescribe to patients with current alcohol or drug overdose. Adjust for hepatic impairment: reduce dose in patients with liver dysfunction. Store at ambient temperature: keep in original container, protect from moisture and light.

Methadone Hydrochloride has notable drug interaction potential that requires careful management.

Major Interactions (Avoid): - CNS depressants (benzodiazepines, alcohol): may cause profound respiratory depression. - MAO inhibitors: risk of severe hypotension and serotonin syndrome. - Strong CYP3A4 inhibitors (ketoconazole, erythromycin): increase methadone plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (rifampin, carbamazepine): may reduce efficacy. - Antidepressants (SSRIs, SNRIs): may enhance serotonergic effects. - QT‑prolonging drugs (certain antiarrhythmics, antipsychotics): may increase risk of cardiac arrhythmia.